A
Agilent Technologies Inc.
NYSE · Healthcare
| Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 | Oct 2020 | Oct 2019 | Oct 2018 | Oct 2017 | Oct 2016 | Oct 2015 | Oct 2014 | Oct 2013 | Oct 2012 | Oct 2011 | Oct 2010 | Oct 2009 | Oct 2008 | Oct 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||||||||||||
| Operating Cash Flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amort. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Comp. | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Changes in WC | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing | |||||||||||||||||||
| Capital Expenditures | 407.0M | 378.0M | 298.0M | 291.0M | 188.0M | 119.0M | 155.0M | 177.0M | 176.0M | 139.0M | 98.0M | 205.0M | 195.0M | 194.0M | 188.0M | 121.0M | 128.0M | 154.0M | 154.0M |
| Acquisitions | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Investing Cash Flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing | |||||||||||||||||||
| Debt Repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Common Stock Issued | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Buybacks | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Summary | |||||||||||||||||||
| Free Cash Flow | 1.15B | 1.37B | 1.47B | 1.02B | 1.30B | 802.0M | 866.0M | 910.0M | 713.0M | 654.0M | 414.0M | 526.0M | 957.0M | 1.03B | 1.07B | 597.0M | 280.0M | 602.0M | 815.0M |
| Net Change in Cash | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |